EBOS Group: How a Christchurch Supplier Became Australasia’s Drug Mover

EBOS Group shows how a company from a small market can become a regional leader in an unglamorous industry by buying well, integrating carefully and accepting that its centre of gravity will move abroad. This article explains the origins of the business, how a wholesaler earns money on government-regulated margins, the acquisitions that built it, what the Chemist Warehouse loss really cost, the FY2026 numbers and the questions facing a company that is New Zealand’s largest by revenue but earns most of it in Australia. It is part of the New Zealand Company Stories hub.

How did EBOS Group begin?

EBOS began in Christchurch in 1922 as Early Brothers, a small trading firm that came to specialise in dental and surgical supplies. The name is a contraction of that original business, and for most of the twentieth century it was a modest regional medical wholesaler.

The company listed on the New Zealand stock exchange in the 1960s and spent decades supplying hospitals, dentists and doctors’ surgeries. It was profitable and small. The transformation began in the 2000s, when management started using the listed shares and a conservative balance sheet to buy adjacent distributors. The purchase of Pharmacy Retailing New Zealand in 2007 brought ProPharma, the country’s largest pharmacy wholesaler, and with it a place at the centre of the New Zealand medicine supply chain.

The second leg, animal care, arrived in 2011 with Masterpet, a distributor and brand owner in pet supplies. That gave EBOS a business with similar logistics but freer pricing, a combination that has shaped its strategy ever since.

How does EBOS Group make money?

EBOS makes most of its money by buying medicines from manufacturers and delivering them to pharmacies and hospitals, usually within hours, for a margin that governments largely fix. Scale, warehouse automation and working-capital discipline turn a tiny percentage into a substantial profit.

Healthcare accounts for about 93% of revenue. In the year to 30 June 2026 the segment produced underlying EBITDA of A$516 million on sales of well over A$12 billion, a margin of roughly 4%. Within it sit several distinct activities:

• Community pharmacy wholesale: Symbion in Australia and ProPharma in New Zealand deliver prescription and over-the-counter products to thousands of pharmacies.
• Pharmacy franchising: TerryWhite Chemmart, a network of more than 500 stores owned by pharmacists and supplied by EBOS.
• Institutional healthcare: hospital medicine distribution and medical devices, including the LifeHealthcare implant business.
• Contract logistics: third-party warehousing and distribution on behalf of pharmaceutical companies.

In Australia, wholesalers that agree to deliver the full range of subsidised medicines to any pharmacy within set times receive payments from a government funding pool. In New Zealand, wholesaler margins sit inside a system shaped by the state buyer described in the Pharmac story. In both countries price is mostly out of the wholesaler’s hands, so profit growth comes from volume, mix and cost.

What acquisitions built the modern EBOS?

Three deals built the modern group: Symbion in 2013, which made EBOS an Australian pharmaceutical wholesaler; the Terry White and Chemmart merger in 2016, which gave it a retail brand; and LifeHealthcare in 2021, which added higher-margin medical devices.

Symbion was the transformation. EBOS paid about NZ$1.1 billion to the Zuellig Group for one of Australia’s three full-line pharmaceutical wholesalers, a company several times its own size. Zuellig took shares as part of the price and became the cornerstone shareholder with roughly 40%. EBOS listed on the ASX the same year. Overnight a New Zealand distributor had become an Australasian one, with most of its revenue across the Tasman.

The following years added pieces around that core. Black Hawk, a premium Australian pet-food brand, was bought in 2014 for A$57.8 million. A controlling interest in Terry White Group came in 2016, merged with the Chemmart banner EBOS already owned, with full ownership following in 2018. In late 2021 EBOS agreed to pay A$1.17 billion for LifeHealthcare in Australia and New Zealand and a controlling stake in Transmedic, a Singapore-based device distributor, taking it into orthopaedic and spinal implants and into South-east Asia.

More recent purchases have been smaller: veterinary wholesaler SVS, the pet-food makers Next Generation Pet Foods and Paringa Pet Foods, and K-Talyst, a medical aesthetics distributor.

Who owns and governs EBOS Group?

EBOS is now a widely held company with no controlling shareholder. Its long-time cornerstone investor, the Zuellig family’s Sybos Holdings, sold down to 4.9% in May 2025, and institutional funds on both sides of the Tasman hold most of the register.

Sybos had held its stake since the Symbion deal and had not sold a share since 2020. In May 2025 it placed about 27 million shares at A$35.50 each, raising roughly A$952 million and describing the sale as diversification. It had not had a board seat for several years. The exit removed an overhang and lifted the free float, which helped EBOS enter the S&P/ASX 200 index in September 2025.

The board is chaired by Elizabeth Coutts, a veteran New Zealand director. Adam Hall became chief executive in 2025, succeeding John Cullity, who had run the group since 2018 and led it through the LifeHealthcare purchase and the Chemist Warehouse loss. The registered office remains in Christchurch, but the executive team sits in Melbourne and the accounts are presented in Australian dollars, a migration of gravity that the NZX story describes as a wider pattern among New Zealand’s largest companies.

Why did EBOS lose the Chemist Warehouse contract?

EBOS lost the contract because its rival Sigma Healthcare offered Chemist Warehouse something EBOS would not: equity. In June 2023 Sigma won the supply agreement from July 2024 and issued shares to the discount chain, the first step towards a full merger of the two.

Chemist Warehouse, Australia’s largest pharmacy retailer with more than 450 stores at the time, had been supplied by EBOS for years. The business was worth about A$1.9 billion to A$2 billion of annual revenue, close to a fifth of the group total. It was also low-margin: a customer of that size negotiates hard, and analysts had long debated how much profit the contract really carried.

Sigma’s bid gave Chemist Warehouse roughly a tenth of Sigma’s shares, and the relationship deepened into a reverse takeover that completed in early 2025, creating a vertically integrated wholesaler, franchisor and retailer worth tens of billions of dollars. EBOS could not have matched that without ceding control. The contract expired at the end of June 2024.

How did EBOS respond to the loss?

EBOS responded by replacing volume with a larger number of smaller, more profitable customers, by growing its own TerryWhite Chemmart network and by leaning on medical devices and animal care. Revenue recovered within a year; earnings per share have taken longer.

In the year to June 2025, the first without Chemist Warehouse, revenue from continuing customers grew strongly and reported group revenue reached A$12.3 billion, with underlying EBITDA up 7.5% to A$585 million. The wholesale business added more than 320 pharmacy accounts and TerryWhite Chemmart added a net 34 stores. Management had warned that competitive pressure in pharmacy wholesale would compress margins, and it has.

The response also exposed the cost of timing. EBOS was midway through a four-year, A$360 million programme to rebuild and automate its distribution centres when its biggest customer left. The programme was completed in FY2026. New sheds bring higher depreciation and, with leverage at 2.1 times earnings, higher interest. That is why underlying EBITDA rose 5% in FY2026 while underlying net profit fell 3.1% and earnings per share fell 7.3% to 121.7 cents.

What do the latest numbers show?

For the year to 30 June 2026, EBOS reported revenue of A$13.5 billion, up 9.9%, underlying EBITDA of A$614 million, up 5.0%, and underlying net profit of A$250 million, down 3.1%. Statutory net profit was A$225.2 million.

Healthcare EBITDA rose 3.2% to A$516 million, helped by community pharmacy demand and growth in high-cost hospital medicines. Animal Care revenue jumped 34.6% to A$907 million, largely because of acquisitions, while its EBITDA grew a more modest 11.6% because the acquired businesses carry lower margins than the established brands.

The final dividend was held at NZ 61.5 cents a share, taking the full-year payout to NZ 118.5 cents. For FY2027 the company has guided to underlying EBITDA of A$635 million to A$655 million, growth of roughly 3% to 7%, with capital expenditure falling to about A$100 million. Mr Hall told investors the group was “moving beyond the peak capital investment phase”, which in plain terms means cash flow should improve before profit does.

Why does a medicine wholesaler own pet-food brands?

EBOS owns pet brands because animal care uses the same logistics skills as healthcare but earns higher margins and is free of government price control. It diversifies the group away from pharmaceutical regulation and gives it products of its own to sell.

The portfolio includes Black Hawk and Vitapet pet foods and treats, the Masterpet distribution business, veterinary wholesalers Lyppard and SVS, and a half share in the New Zealand pet retailer Animates. With revenue of A$907 million in FY2026, Animal Care is still small beside Healthcare but contributes a disproportionate share of profit.

The recent acquisitions of Next Generation Pet Foods and Paringa Pet Foods push EBOS further into manufacturing, so that it captures the producer’s margin as well as the distributor’s. The risk is cyclical: premium pet food is discretionary, and management acknowledged in 2025 that pressure on household budgets had slowed sales of its dearer ranges. Pet owners trade down more readily than patients do.

Who competes with EBOS Group?

In Australian pharmaceutical wholesale EBOS competes with Sigma Healthcare, now merged with Chemist Warehouse, and Australian Pharmaceutical Industries, owned by the conglomerate Wesfarmers since 2022. Three full-line wholesalers serve the market, and two of them now belong to much larger retail groups.

That is a material change from a decade ago, when the three wholesalers were of roughly similar standing. Wesfarmers brings a balance sheet and retail expertise to API and its Priceline banner. Sigma brings the buying power of the country’s dominant discounter. EBOS is the only one of the three that remains primarily a distributor, which makes it the natural partner for independent pharmacists who do not want to be supplied by a competitor.

In New Zealand, ProPharma is the largest wholesaler in a small market, where retail pharmacy is itself being reshaped by discount chains and by supermarkets, discussed in the article on the supermarket duopoly. In medical devices EBOS competes with the direct sales arms of global manufacturers and with other specialist distributors. In logistics, its discipline and culture invite comparison with Mainfreight, the other New Zealand company that built an international network out of warehouses and trucks.

What are the main risks facing EBOS?

The main risks are regulatory changes to medicine pricing and pharmacy remuneration, customer concentration, the cost of capital tied up in inventory and warehouses, and integration risk from continued acquisitions. Each bears on a margin that is thin to begin with.

Government policy is the largest. Australia’s medicine subsidy scheme periodically cuts the prices of off-patent drugs, which reduces the dollar value on which wholesaler margins are calculated. The move to 60-day dispensing for many common medicines halved the number of pharmacy visits for those prescriptions. Community pharmacy agreements, negotiated every few years between the government and pharmacy owners, set the terms for the whole chain.

Debt is a second consideration. Leverage of 2.1 times is inside the target range of 1.7 to 2.3 times but higher than the 1.9 times of a year earlier, and it leaves less room for a large acquisition without new equity. Third, the device business depends on agency agreements with overseas manufacturers that can be withdrawn if a supplier decides to sell direct.

What can founders and CFOs learn from EBOS Group?

The lesson is that a small-market company can build regional scale through disciplined acquisition, provided it buys businesses it understands, funds them conservatively and accepts that management and investors will follow revenue offshore.

1. Buy one size up, rarely. Symbion was a bet-the-company deal, made once, with the vendor taking shares and so sharing the risk. Most other purchases have been small bolt-ons.
2. Never let one customer write your budget. A contract worth a fifth of revenue gave Chemist Warehouse leverage that ended in a competitor offering equity. Concentration looks like scale until renewal.
3. Diversify into adjacent margin pools. Devices and pet care use the same warehouses and systems as wholesale but are priced by the market rather than a regulator.
4. Time capital programmes with humility. The warehouse rebuild was justified, but it landed alongside a volume loss. CFOs should stress-test large capital projects against the loss of the top customer.
5. Report an underlying measure, and reconcile it. EBOS presents underlying and statutory profit side by side, which lets investors see both the operating trend and the cost of one-off items.

The broader point for founders is about ambition. Wholesale distribution is not fashionable, yet it has produced a company with more revenue than Fisher & Paykel Healthcare and Ryman Healthcare combined several times over.

What happens next for EBOS Group?

The next two years should show whether the investment phase pays off. With the warehouse programme complete and capital spending falling to about A$100 million, the test is whether earnings per share resume growing and leverage drifts back towards the middle of the target range.

Guidance for FY2027 points to underlying EBITDA of A$635 million to A$655 million. Beyond that, three questions stand out. One is whether the new chief executive pursues another large acquisition, most plausibly in medical technology or in South-east Asia, where Transmedic gives a base. A second is whether the enlarged Sigma group turns its attention to independent pharmacies. A third is the listing itself: with Zuellig largely gone, the ASX 200 inclusion secured and most investors and earnings in Australia, pressure to make Australia the primary home is likely to grow.

None of that changes the essential character of the business. EBOS earns a small margin on an enormous, steadily growing flow of medicines to ageing populations. The model is dull, defensive and hard to dislodge, which is precisely what its shareholders have paid for.

Frequently Asked Questions